FDA Clearance Tracker · K232544
Apollo ESG NXT System, Apollo REVISE NXT System
Last checked: Nov 20, 2026Latest source record: Sep 18, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Sep 18, 2023
Substantially Equivalent
Time to decision
27 days
Received Aug 22, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K232544
- Device name
- Apollo ESG NXT System, Apollo REVISE NXT System
- Applicant
- Apollo Endosurgery, Inc.
- Applicant location
- Austin, TX
- Received
- Aug 22, 2023
- Decided
- Sep 18, 2023
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device class
- Class II
- Regulation
- 21 CFR 876.5983
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QTD. The earliest in FDA's data is DEN210045, decided Jul 12, 2022.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K232544
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Apollo Endosurgery, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K231553 · Decided Jun 29, 2023 · 30 days after receipt
Device type: Endoscopic Tissue Approximation Device (OCW) · GI, Urology & Nephrology
- APOLLO ESG System, APOLLO ESG SX System, APOLLO REVISE System, APOLLO REVISE SX SystemNew device typeDe Novo
DEN210045 · Decided Jul 12, 2022 · 285 days after receipt
Device type: Endoscopic Suturing Device For Altering Gastric Anatomy For Weight Loss (QTD) · GI, Urology & Nephrology
K210266 · Decided Mar 2, 2021 · 29 days after receipt
Device type: Endoscopic Tissue Approximation Device (OCW) · GI, Urology & Nephrology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.